RHHBY - RemeGen candidate Fast Track'd for lupus April, 15 2020 11:13 AM Roche Holding Ltd ADR The FDA has signed off on Fast Track status for Yantai, China-based RemeGen's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE).More news on: GlaxoSmithKline plc, Mallinckrodt plc, Biogen Inc., Healthcare stocks news, Read more ...